Human HVEM & NF-κB Reporter Recombinant Cell Line, Jurkat (CAT#: IOC-LX153)

Creative Biolabs has developed several immune checkpoint stable cell Lines expressing the most popular immune checkpoints to accelerate clients' immunotherapy discovery and clinical translation. The HVEM cell line is a recombinant clonal stable Jurkat T cell line expressing firefly luciferase gene under the control of 4 copies of NF-κB response elements with constitutive expression of human HVEM (Herpes Virus Entry Mediator, Tumor Necrosis Factor Receptor Superfamily Member 14, TNFRSF14, CD270, GenBank Accession No. NM_003820). Following activation by human HVEM ligand LIGHT, NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase reporter gene. Which can be used in binding assays and functional assay.

Stable cell lines for increased reliability and reproducibility;
Protein expression at the cell surface validated by FACS or WB;

•Screen for agonists or antagonists of LIGHT-HVEM signaling in a physiological relevant cellular context
•Characterize T cell-mediated immune responses of HVEM and its interactions with LIGHT

•Screen co-stimulatory immune checkpoint molecules

Human

Jurkat

HVEM & NF-κB Reporter

HVEM is a bidirectional switch regulating T-cell activation in a costimulatory or coinhibitory fashion whose outcome depends on the binding partner. HVEM can act as both receptor and ligand, the binding of endogenous ligand LIGHT or agonist antibodies to HVEM delivers a costimulatory signal; whereas the binding of HVEM to BTLA (IgSF) or CD160 on Effector T cells delivers a coinhibitory signal. LIGHT/HVEM axis are co-stimulatory immune checkpoint molecules extensively studied for cancer immunotherapy; LIGHT, either in the soluble form or oligomers expressed on the cell surface, can activate NF-kB through binding to HVEM; we have shown that LIGHT expressing cells are more potent and efficacious than the soluble LIGHT for activating HVEM overexpressed on Jurkat cell surface.